Dual antiplatelet therapy (DAPT) with acetylsalicylic acid (ASA) and a P2Y12 inhibitor reduces ischemic events and death in patients with acute coronary syndrome (ACS) and is recommended in the current guidelines for all ACS patients without contraindications, including those undergoing coronary artery bypass grafting (CABG).1,2 The recommended duration of DAPT for patients with ACS undergoing CABG is 12 months, and the use of a more potent P2Y12 inhibitor (eg, ticagrelor or prasugrel) is recommended over clopidogrel.1,2. This evidence concerns the gene P2RY12 and acute coronary syndrome.